When Even the Experts Disagree…Who Benefits from Adjuvant Chemotherapy
Data presented at the San Antonio Breast Cancer Symposium show that basically all women with HER2+ breast cancers benefit from adjuvant chemotherapy/Herceptin due to their worse prognosis. In my mind, however, there is no more controversial area in breast cancer than in which patients truly benefit from receiving adjuvant chemotherapy, among women... Read more
